Clinical Guidelines for Dental Management of Antiresorptive Therapy

Abstract

Antiresorptive therapy, including bisphosphonates and denosumab, has become a cornerstone in the management of osteoporosis and metastatic bone diseases. However, these agents are associated with complications such as medication-related osteonecrosis of the jaw (MRONJ), necessitating specialized dental management. This review provides a comprehensive evaluation of current clinical guidelines, integrating recent evidence on risk assessment, preventive strategies, and multidisciplinary care models. Emphasis is placed on the pathophysiological mechanisms of MRONJ, clinical risk stratification, and practical recommendations for dental practitioners managing patients on antiresorptive therapy. The aim is to deliver actionable, evidence-based guidance for healthcare professionals seeking to optimize patient outcomes and reduce complications.

Introduction

Antiresorptive agents, particularly bisphosphonates and denosumab, are widely utilized for preventing skeletal-related events in patients with osteoporosis, Paget’s disease, and malignancies with osseous metastases. Despite their proven efficacy, these medications carry the risk of MRONJ, a serious and sometimes debilitating complication. The dental management of patients receiving antiresorptive therapy requires a thorough understanding of the pharmacological profile of these agents, the underlying mechanisms of jawbone pathology, and the latest evidence-based guidelines. This article systematically reviews the epidemiology, pathophysiology, risk factors, clinical features, diagnostic criteria, and management strategies, culminating in a concise synthesis of current clinical recommendations.

Epidemiology / Disease Burden

The prevalence of MRONJ varies according to the underlying indication for antiresorptive therapy and the route of drug administration. In cancer patients receiving high-dose intravenous bisphosphonates or denosumab, the incidence ranges from 1% to 9%, while in osteoporotic patients on oral bisphosphonates, the risk is significantly lower, estimated at 0.01% to 0.1%. Despite a relatively low overall incidence, the clinical and economic burden of MRONJ is substantial due to chronic pain, impaired function, and the complexity of management. Epidemiological studies suggest increasing awareness and diagnosis, but also highlight the need for standardized preventive measures and early intervention strategies.

Pathophysiology

Antiresorptive agents disrupt normal bone remodeling by inhibiting osteoclast-mediated bone resorption. Bisphosphonates bind to hydroxyapatite and are internalized by osteoclasts, leading to apoptosis and reduced bone turnover. Denosumab, a monoclonal antibody against RANKL, prevents osteoclast differentiation and function. The jawbones, with their high remodeling rates and frequent exposure to microtrauma, are particularly susceptible. Impaired remodeling, coupled with suppression of angiogenesis and immune response, fosters an environment conducive to osteonecrosis, especially in the setting of dental extractions or infections. Understanding these mechanisms is critical for risk mitigation and targeted intervention.

Risk Factors

Several factors increase the risk of MRONJ in patients receiving antiresorptive therapy. High cumulative dose, prolonged duration of treatment, intravenous administration, and concomitant corticosteroid or antiangiogenic therapy are significant pharmacological risk enhancers. Local risk factors include invasive dental procedures (such as extractions), periodontal disease, poor oral hygiene, and ill-fitting dentures. Systemic risk factors comprise advanced age, cancer diagnosis, diabetes mellitus, smoking, and immunosuppression. A comprehensive risk assessment should integrate both systemic and local factors to inform individualized preventive and treatment strategies.

Clinical Features

MRONJ typically presents as exposed necrotic bone in the maxillofacial region persisting for more than eight weeks in patients with a history of antiresorptive therapy who have not received radiation therapy to the jaws. Symptoms may include pain, swelling, purulent discharge, loose teeth, and non-healing extraction sockets. In advanced cases, pathological fractures, oroantral fistulae, and secondary infections may occur. Early identification of preclinical or prodromal signs, such as mucosal erythema or periodontal symptoms, is essential for timely intervention.

Diagnosis

The diagnosis of MRONJ is primarily clinical, based on the criteria established by professional bodies such as the American Association of Oral and Maxillofacial Surgeons (AAOMS). Imaging modalities, including panoramic radiographs and cone-beam CT, are valuable for assessing the extent of bone involvement and planning surgical interventions. Laboratory investigations may be used to rule out alternative diagnoses. Early-stage lesions may be subtle and require a high index of suspicion, particularly in at-risk individuals undergoing dental procedures.

Treatment & Management

Management strategies are dictated by the stage of MRONJ, symptomatology, and patient comorbidities. Conservative therapy, including antimicrobial mouth rinses, systemic antibiotics, and pain control, is preferred for early-stage or asymptomatic cases. Surgical intervention, such as sequestrectomy or resection, is reserved for refractory or advanced disease. Dental practitioners should prioritize preventive dental care before initiating antiresorptive therapy, including the elimination of oral infections and completion of invasive procedures. During therapy, non-invasive dental treatments are encouraged, and extractions should be performed with caution, employing atraumatic techniques and primary closure when feasible.

Recent Advances / Emerging Therapies

Recent research has focused on identifying biomarkers for susceptibility, optimizing drug holiday protocols, and exploring adjunctive therapies such as platelet-rich plasma, laser therapy, and teriparatide. There is emerging evidence supporting the use of minimally invasive surgical techniques and local application of growth factors to enhance healing. The concept of drug holidays remains controversial, with individualized risk-benefit analysis required. Ongoing clinical trials aim to refine stratification tools and validate novel interventions to reduce MRONJ incidence.

Guideline Recommendations

Major professional organizations, including the AAOMS, the American Dental Association (ADA), and international consensus panels, provide evidence-based guidelines for dental management of patients on antiresorptive therapy. Key recommendations include thorough dental evaluation and necessary treatment before initiation of therapy, regular follow-up and oral hygiene maintenance, risk stratification based on indication and duration of therapy, and conservative surgical protocols. Multidisciplinary collaboration between oncologists, endocrinologists, dentists, and oral surgeons is emphasized to ensure optimal patient care. Patient education on symptoms and prompt reporting of oral complications is integral to successful outcomes.

Conclusion

The dental management of patients on antiresorptive therapy demands a proactive, evidence-based approach centered on risk assessment, preventive care, and multidisciplinary collaboration. With growing use of these agents in diverse populations, adherence to clinical guidelines is essential to minimize the incidence and morbidity of MRONJ. Ongoing research into pathophysiology, risk stratification, and novel therapies will continue to inform best practices and improve patient outcomes in this challenging clinical context.